What is it about?
A paradigm shift in asthma management which addresses the inherent problems associated with the use of short acting beta-agonist therapy is required. Consideration needs to be given to replacing short acting beta-agonist reliever therapy reliever with ICS/fast-onset beta agonist reliever therapy across the range of asthma severity.
Featured Image
Photo by Hush Naidoo on Unsplash
Why is it important?
ICS/fast-onset beta agonist reliever therapy is both safer and more effective than short acting beta-agonist therapy in adult asthma, across the spectrum of severity. A paradigm change in the approach to asthma management that incorporates this evidence is now required.
Read the Original
This page is a summary of: Asthma paradoxes: time for a new approach across the spectrum of asthma severity, European Respiratory Journal, April 2019, European Respiratory Society (ERS),
DOI: 10.1183/13993003.00218-2019.
You can read the full text:
Contributors
The following have contributed to this page
